QUEBEC CITY, Canada, March 15 /PRNewswire-FirstCall/ - Atrium Biotechnologies Inc. filed with Canadian securities regulators its full year 2005 management’s discussion and analysis (“MD&A”) and audited financial statements. Concurrent with the above mentioned filings, Atrium has also posted the quarterly income statements in US dollars for 2004 and 2005 as well as such full year 2005 MD&A and audited financial statements in the “Investor Relations” section its website at www.atrium-bio.com, under “Financial reports”.
Board of Directors
Pierre Laurin, Chairman of the Board of Atrium, announced the appointment of Yves Julien to Atrium’s Board. Mr. Julien has been a corporate financial consultant since 1999. He was former Managing Director at Merrill Lynch where he worked from 1981 to 1998. “We are delighted to be able to count on Mr. Julien’s finance expertise and vast business experience to pursue our strategic plan”, stated Pierre Laurin.
About Atrium
Atrium Biotechnologies Inc. is a leading developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutrition industries. Atrium focuses primarily on growing segments of the health and personal care markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of active ingredients, specialty chemicals and health and nutrition finished products through its highly specialized sales and marketing network in more than 40 countries, primarily in North America, Europe and Asia. Atrium has close to 500 employees and operates three manufacturing facilities. Additional information about Atrium is available on its Web site at www.atrium-bio.com.
ATRIUM BIOTECHNOLOGIES INC.
CONTACT: Investor Relations: John Dempsey, Vice President, Finance andChief Financial Officer, (418) 652-1116, ext. 287, jdempsey@atrium-bio.com;Media Relations: Simon Poitras, HKDP, (418) 523-3352, ext. 239,spoitras@hkdp.qc.ca
